- Short report
- Open Access
Immunosuppression abrogates resistance of young rabbits to Rabbit Haemorrhagic Disease (RHD)
© Marques et al.; licensee BioMed Central Ltd. 2014
- Received: 30 July 2013
- Accepted: 21 January 2014
- Published: 4 February 2014
Rabbit Haemorrhagic Disease (RHD) is caused by a calicivirus (RHDV) that kills 90% of infected adult European rabbits within 3 days. Remarkably, young rabbits are resistant to RHD. We induced immunosuppression in young rabbits by treatment with methylprednisolone acetate (MPA) and challenged the animals with RHDV by intramuscular injection. All of these young rabbits died within 3 days of infection due to fulminant hepatitis, presenting a large number of RHDV-positive dead or apoptotic hepatocytes, and a significant seric increase in cytokines, features that are similar to those of naïve adult rabbits infected by RHDV. We conclude that MPA-induced immunosuppression abrogates the resistance of young rabbits to RHD, indicating that there are differences in the innate immune system between young and adult rabbits that contribute to their distinct resistance/susceptibility to RHDV infection.
- Disseminate Intravascular Coagulation
- TUNEL Assay
- Disseminate Intravascular Coagulation
- Fulminant Hepatitis
- Adult Rabbit
Rabbits of the species Oryctolagus cuniculus are the natural hosts of the Rabbit Haemorrhagic Disease Virus (RHDV). This virus targets the liver of rabbits and causes the death of millions of wild and domestic adult rabbits worldwide [1–3]. Usually, adult rabbits die within 3 days of RHDV infection as a result of fulminant hepatitis, showing no symptoms of the disease until a few hours before death. Interestingly, young rabbits (less than 4 weeks-old) are resistant to Rabbit Haemorrhagic Disease (RHD), developing only a sub-clinical disease to the viral infection [3–6]. A central issue in the pathogenesis of RHD is to understand this age-related resistance to a viral infection that is fatal in adult animals. Pertinent to this issue, Ruvoën-Clouet et al.  reported that RHDV is capable of binding to histo-blood group antigens (HBGA) that are expressed on the mucosa of the upper respiratory and digestive tracts of adult rabbits, and they have postulated that the density of these attachment factors on mucosal cells is essential for adult rabbits to be susceptible to RHDV infection. In agreement with their view, they found only a weak binding of virus particles to the same mucosal tissues in young rabbits, thus indicating that low expression of HBGA could explain the resistance of young animals to RHD. Nevertheless, and despite this evidence, they recently reported that low expression of these facilitating factors of the infection, at the epithelial level, only confers partial protection against RHDV infection [3, 8]. They also showed that hepatocytes, the main target of RHDV replication, do not express HBGA [7, 8], which led them to suggest the existence of additional hepatic cellular receptor(s) for the virus . Additionally, we demonstrated that young rabbits infected with RHDV by the intramuscular route develop the exact same mild liver disease that we had observed in young rabbits infected with RHDV by natural, oral and nasal routes [4, 9–12]. This made us consider that resistance of young rabbits to RHD may depend on additional putative factors. A difference in innate immunity is one of these possible factors, since previous data have shown that young and adult rabbits develop different immune responses after RHDV infection [4–6, 13–16]. Thus, we decided to study whether altering the immune physiology of young rabbits by methylprednisolone acetate (MPA)-induced immunosuppression would interfere with the resistance of young rabbits to RHDV infection.
New Zealand white rabbits (Oryctolagus cuniculus) were used when the animals were 4 weeks old. The rabbits were kept under standard conditions of housing with unrestricted access to food and water; this was done according to the European Union Directive no. 2010/63/CE and was approved by the appropriate local ethic committee (“Comité de Ética do ICBAS/UP”). The inoculum of RHDV (Ast/89 strain) was obtained as previously described by Teixeira et al.  and had a 210 titre in haemagglutination units (HAU). Fourteen young rabbits (24 days) were immunosuppressed with an intramuscular injection of a suspension of MPA a long-acting corticosteroid (Depo-Medrol®; 20 mg/kg). All animals were also injected subcutaneously with a broad spectrum antibiotic, enrofloxacine (Alsir® 2.5%; 10 mg/kg), in order to prevent secondary bacterial infections. One week later, 9 of the 14 immunosuppressed rabbits were challenged with 100 μL of RHDV injected intramuscularly. The other 5 young rabbits were used as controls of the immunosuppression, i.e. they were euthanized and their thymuses were collected and weighed in relation with the body weight of the rabbits . Another group of 15 young rabbits were used as the control of the infection or of the experiment. Ten animals were inoculated, injected intramuscularly, with 100 μL of RHDV, and the other 5 were inoculated, injected intramuscularly, with 100 μL of PBS, at the same time of the immunosuppressed rabbits. Five of the infected rabbits also received the antibiotic, according to the same scheme of the immunosuppressed rabbits. All the animals were observed regularly, and clinical manifestations of RHD were monitored. After the animal’s death, by disease or euthanasia (as described by Marques et al. ), the presence of macroscopic lesions compatible with RHD was investigated. Fragments of the thymus, spleen and liver were collected for histopathological and TUNEL analysis as described below. Blood samples were obtained from the vena cava caudal in order to quantify the seric level of cytokines (TNF-α, IL-6 and IL-10) by ELISA (ELISA Kit, Uscn Life Science Inc., Wuhan, People’s Republic of China) in 3 of the experimental groups: PBS control rabbits, immunosuppressed rabbits and immunosuppressed, RHDV-infected young rabbits. Liver samples of immunosuppressed, RHDV-infected young rabbits and infected young rabbits were also collected to quantify the presence of RHDV antigen by ELISA (the viral titer corresponding to the threshold value of dilution at which the sample is considered positive to RHDV, i.e., when its value is superior to the calculated cut-off (0.2 × OD405nm positive control sample; INGEZIM RHDV 17.RHD.K2 kit, Ingenasa, Madrid, Spain). Other liver samples were fixed by 10% buffered formalin, dehydrated through graded alcohols and xylene and embedded in paraffin wax by standard methods. These were used for light microscopy studies that included immunocytochemistry for RHDV antigen (protocol described by Marques et al. ) and TUNEL assay for apoptosis detection (protocol described according to the manufacturer’s instructions (TdT in situ - DAB In Situ Apoptosis Detection Kit, R&D Systems Europe, Ltd., Abingdon, United Kingdom)). Samples of the spleen and thymus were also fixed with 10% buffered formalin to be used for apoptosis detection by the TUNEL assay. Statistical comparison of data from all groups of rabbits was performed using an unpaired t-test calculated with GraphPad Prism, version 5.0a, software. Differences were considered significant at p < 0.05.
RHDV infection kills most adult rabbits, whereas young rabbits show no disease [4, 5, 12]. Our previous reports on the pathogenesis of RHD [5, 6, 14–16] indicated that young and adult rabbits may differ in innate immune response, since the adult animals usually die in less than 3 days (a too early timing for the host to mount a specific immune response to the infectious agent). To investigate a putative role of innate immunity in the resistance of young rabbits, we decided to investigate whether immunosuppression would change the progress of calicivirus infection in these animals. For that, we studied rabbits treated with MPA, a corticosteroid of long-duration, with pleiotropic actions including immunosuppression due to inhibition of the inflammatory response and depletion of both T and B cells [19, 20].
We found that young rabbits under MPA-immunosuppression died from RHDV infection within 3 days, just as naïve adult rabbits do after RHDV inoculation. The animals died from fulminant hepatitis that was associated with widespread apoptosis and disseminated intravascular coagulation (DIC). The inflammatory infiltrates in the liver of the immunosuppressed, RHDV-infected young rabbits were mainly constituted by heterophils, contrary to what would be expected in infected young rabbits, i.e., where liver infiltrates contain macrophages and lymphocytes [3, 4, 6]. These features mimic the typical pathology of RHD in adult rabbits after being infected by RHDV [12, 14, 21]. Also, similarly to infected adult rabbits, the immunosuppressed, RHDV-infected young rabbits showed a marked dissemination of RHDV throughout the liver. The viral titers registered in the liver of immunosuppressed, RHDV-infected young rabbits were also similar to those found in infected adult rabbits. These data show that young rabbits that are treated with MPA develop the full blown RHD seen in adult animals after RHDV infection. This change of young rabbits from resistance to susceptibility to the calicivirus is likely to result from impairment of their innate immunity, i.e., the MPA treatment could, for example, be interfering with the process of antigen presentation, with the phagocytic activity, or with the effector roles of activated NK cells, NK T cells or possibly CD8+ T cells [22–25]. Our results weaken the hypothesis that resistance of young rabbits to RHD derives from a different expression of the viral hepatic cellular receptor(s), since the MPA treatment of the young rabbits made the RHDV capable of infecting the hepatocytes, as observed in adult rabbits.
We also report here a marked increase in proinflammatory and anti-inflammatory cytokines (TNF-α, IL-6 and IL-10) in the serum of the immunosuppressed, RHDV-infected young rabbits. This enhancement in cytokines is similar to what occurs in the blood of infected adult rabbits a few hours prior to death. Others have previously shown that RHDV infection of adult rabbits is related to a strong increase of mRNA levels of pro-inflammatory cytokines in the liver, target organ of viral replication [26, 27]. The histopathological signs of fulminant hepatitis observed in the immunosuppressed, RHDV-infected young rabbits, similarly to what happens in adult rabbits having died from RHD, involved numerous apoptotic liver cells that are due to the cytopathic effect of viral replication and the exacerbated inflammatory response caused by the deregulated expression of cytokines detected in these animals, TNF-α in particular, since it is a well-known cell death mediator [26, 27]. A similar phenomenon is seen in B hepatitis, where secretion of TNF-α by macrophages and infected hepatocytes contributes to liver cell death [28, 29]. In contrast, young rabbits that are infected with RHDV present an early and only mild increase of proinflammatory cytokines . This corroborates the idea that RHDV infection in young rabbits is associated with an early and adequate inflammatory immune response that may be vital in strongly limiting viral replication, and consequently allowing the more than 3 days that are required for the rabbits to develop a specific immune response against RHDV, similarly to what is observed in the few survivors of Ebola virus infection [10, 30].
In conclusion, we demonstrate that the innate immune response of young rabbits is abrogated by the MPA treatment, changing young rabbits into hosts that become as susceptible to fatal calicivirus infection as naïve adult rabbits are. Thus we propose that the resistance of young rabbits to RHDV-infection is mediated by their particular innate immunity that is different from that of adult rabbits. Moreover, this discovery opens the way for a better understanding of the rationale of resistance of young rabbits to RHD.
We are grateful to Prof. Francisco Parra (University of Oviedo) for the offer of the initial sample of RHDV suspension that was used to infect the rabbits. We thank Ms. Manuela Silva and Ana Pinto for their excellent technical assistance. This work was funded by FCT – Portugal, grant no. PTDC/CVT/122905/2010, COMPETE and FEDER. Luzia Teixeira was supported by Fundo Social Europeu and MCTES through POPH-QREN Tipologia 4.2.
- Ohlinger VF, Haas B, Meyers G, Weiland F, Thiel HJ: Identification and characterization of the virus causing rabbit hemorrhagic disease. J Virol. 1990, 64: 3331-3336.PubMed CentralPubMedGoogle Scholar
- Parra F, Prieto M: Purification and characterization of a calicivirus as the causative agent of a lethal hemorrhagic disease in rabbits. J Virol. 1990, 64: 4013-4015.PubMed CentralPubMedGoogle Scholar
- Abrantes J, van der Loo W, Le Pendu J, Esteves PJ: Rabbit haemorrhagic disease (RHD) and rabbit haemorrhagic disease virus (RHDV): a review. Vet Res. 2012, 43: 12-10.1186/1297-9716-43-12.PubMed CentralView ArticlePubMedGoogle Scholar
- Mikami D, Park JH, Kimura T, Ochiai K, Itakura C: Hepatic lesions in young rabbits experimentally infected with rabbit haemorrhagic disease virus. Res Vet Sci. 1999, 66: 237-242. 10.1053/rvsc.1998.0266.View ArticlePubMedGoogle Scholar
- Ferreira PG, Costa-e-Silva A, Monteiro E, Oliveira MJ, Aguas AP: Transient decrease in blood heterophils and sustained liver damage caused by calicivirus infection of young rabbits that are naturally resistant to rabbit haemorrhagic disease. Res Vet Sci. 2004, 76: 83-94. 10.1016/j.rvsc.2003.08.003.View ArticlePubMedGoogle Scholar
- Ferreira PG, Costa-e-Silva A, Oliveira MJ, Monteiro E, Aguas AP: Leukocyte-hepatocyte interaction in calicivirus infection: differences between rabbits that are resistant or susceptible to rabbit haemorrhagic disease (RHD). Vet Immunol Immunopathol. 2005, 103: 217-221. 10.1016/j.vetimm.2004.09.028.View ArticlePubMedGoogle Scholar
- Ruvoën-Clouet N, Ganière JP, André-Fontaine G, Blanchard D, Le Pendu J: Binding of rabbit hemorrhagic disease virus to antigens of the ABH histo-blood group family. J Virol. 2000, 74: 11950-11954. 10.1128/JVI.74.24.11950-11954.2000.PubMed CentralView ArticlePubMedGoogle Scholar
- Nyström K, Le Gall-Reculé G, Grassi P, Abrantes J, Ruvoën-Clouet N, Le Moullac-Vaidye B, Lopes AM, Esteves PJ, Strive T, Marchandeau S, Dell A, Haslam SM, Le Pendu J: Histo-blood group antigens act as attachment factors of rabbit hemorrhagic disease virus infection in a virus strain-dependent manner. PLoS Pathog. 2011, 7: e1002188-10.1371/journal.ppat.1002188.PubMed CentralView ArticlePubMedGoogle Scholar
- Smid B, Valicek L, Rodak L, Stepanek J, Jurak E: Rabbit haemorrhagic disease: an investigation of some properties of the virus and evaluation of an inactivated vaccine. Vet Microbiol. 1991, 26: 77-85. 10.1016/0378-1135(91)90043-F.View ArticlePubMedGoogle Scholar
- Shien JH, Shieh HK, Lee LH: Experimental infections of rabbits with rabbit haemorrhagic disease virus monitored by polymerase chain reaction. Res Vet Sci. 2000, 68: 255-259. 10.1053/rvsc.1999.0372.View ArticlePubMedGoogle Scholar
- Ferreira PG, Costa-e-Silva A, Aguas AP: Liver disease in young rabbits infected by calicivirus through nasal and oral routes. Res Vet Sci. 2006, 81: 362-365. 10.1016/j.rvsc.2006.02.001.View ArticlePubMedGoogle Scholar
- Prieto JM, Fernandez F, Alvarez V, Espi A, Garcia Marin JF, Alvarez M, Martin JM, Parra F: Immunohistochemical localisation of rabbit haemorrhagic disease virus VP-60 antigen in early infection of young and adult rabbits. Res Vet Sci. 2000, 68: 181-187. 10.1053/rvsc.1999.0357.View ArticlePubMedGoogle Scholar
- Huang HB: Vaccination against and immune response to viral haemorrhagic disease of rabbits: a review of research in the People’s Republic of China. Rev Sci Tech. 1991, 10: 481-498.PubMedGoogle Scholar
- Ferreira PG, Costa-e-Silva A, Oliveira MJ, Monteiro E, Cunha EM, Aguas AP: Severe leukopenia and liver biochemistry changes in adult rabbits after calicivirus infection. Res Vet Sci. 2006, 80: 218-225. 10.1016/j.rvsc.2005.05.007.View ArticlePubMedGoogle Scholar
- Marques RM, Costa ESA, Aguas AP, Teixeira L, Ferreira PG: Early acute depletion of lymphocytes in calicivirus-infected adult rabbits. Vet Res Commun. 2010, 34: 659-668. 10.1007/s11259-010-9437-7.View ArticlePubMedGoogle Scholar
- Marques RM, Costa-E-Silva A, Aguas AP, Teixeira L, Ferreira PG: Early inflammatory response of young rabbits attending natural resistance to calicivirus (RHDV) infection. Vet Immunol Immunopathol. 2012, 150: 181-188. 10.1016/j.vetimm.2012.09.038.View ArticlePubMedGoogle Scholar
- Teixeira L, Marques RM, Aguas AP, Ferreira PG: A simple and rapid method for isolation of caliciviruses from liver of infected rabbits. Res Vet Sci. 2011, 91: 164-166. 10.1016/j.rvsc.2010.08.004.View ArticlePubMedGoogle Scholar
- Kishimoto C, Thorp KA, Abelmann WH: Immunosuppression with high-doses of cyclophosphamide reduces the severity of myocarditis but increases the mortality in murine Coxsackievirus-B3 myocarditis. Circulation. 1990, 82: 982-989. 10.1161/01.CIR.82.3.982.View ArticlePubMedGoogle Scholar
- Miller TA, Schaefer FW: Characterization of a single dose methylprednisolone acetate immune suppression model using Cryptosporidium muris and Cryptosporidium parvum. Vet Parasitol. 2006, 141: 66-83. 10.1016/j.vetpar.2006.04.016.View ArticlePubMedGoogle Scholar
- Miller TA, Schaefer FW: Methylprednisolone acetate immune suppression produces differing effects on Cryptosporidium muris oocyst production depending on when administered. Vet Parasitol. 2007, 149: 77-84. 10.1016/j.vetpar.2007.07.005.View ArticlePubMedGoogle Scholar
- Mitro S, Krauss H: Rabbit hemorrhagic disease: a review with special reference to its epizootiology. Eur J Epidemiol. 1993, 9: 70-78. 10.1007/BF00463093.View ArticlePubMedGoogle Scholar
- Kakimi K, Guidotti LG, Koezuka Y, Chisari FV: Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J Exp Med. 2000, 192: 921-930. 10.1084/jem.192.7.921.PubMed CentralView ArticlePubMedGoogle Scholar
- Thimme R, Wieland S, Steiger C, Ghrayeb J, Reimann KA, Purcell RH, Chisari FV: CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol. 2003, 77: 68-76. 10.1128/JVI.77.1.68-76.2003.PubMed CentralView ArticlePubMedGoogle Scholar
- Freeman BE, Hammarlund E, Raue HP, Slifka MK: Regulation of innate CD8+ T-cell activation mediated by cytokines. Proc Natl Acad Sci U S A. 2012, 109: 9971-9976. 10.1073/pnas.1203543109.PubMed CentralView ArticlePubMedGoogle Scholar
- Heydtmann M: Macrophages in hepatitis B and hepatitis C virus infections. J Virol. 2009, 83: 2796-2802. 10.1128/JVI.00996-08.PubMed CentralView ArticlePubMedGoogle Scholar
- Sanchez-Campos S, Alvarez M, Culebras JM, Gonzalez-Gallego J, Tunon MJ: Pathogenic molecular mechanisms in an animal model of fulminant hepatic failure: rabbit hemorrhagic viral disease. J Lab Clin Med. 2004, 144: 215-222. 10.1016/j.lab.2004.07.006.View ArticlePubMedGoogle Scholar
- Garcia-Lastra R, San-Miguel B, Crespo I, Jorquera F, Alvarez M, Gonzalez-Gallego J, Tunon MJ: Signaling pathways involved in liver injury and regeneration in rabbit hemorrhagic disease, an animal model of virally-induced fulminant hepatic failure. Vet Res. 2010, 41: 2-10.1051/vetres/2009050.View ArticlePubMedGoogle Scholar
- González-Amaro R, García-Monzón C, García-Buey L, Moreno-Otero R, Alonso JL, Yagüe E, Pivel JP, López-Cabrera M, Fernández-Ruiz E, Sánchez-Madrid F: Induction of tumor necrosis factor alpha production by human hepatocytes in chronic viral hepatitis. J Exp Med. 1994, 179: 841-848. 10.1084/jem.179.3.841.View ArticlePubMedGoogle Scholar
- Lara-Pezzi E, Majano PL, Gomez-Gonzalo M, Garciia-Monzon C, Moreno-Otero R, Levrero M, Lopez-Cabrera M: The hepatitis B virus X protein up-regulates tumor necrosis factor alpha gene expression in hepatocytes. Hepatology. 1998, 28: 1013-1021. 10.1002/hep.510280416.View ArticlePubMedGoogle Scholar
- Baize S, Leroy EM, Georges AJ, Georges-Courbot MC, Capron M, Bedjabaga I, Lansoud-Soukate J, Mavoungou E: Inflammatory responses in Ebola virus-infected patients. Clin Exp immunol. 2002, 128: 163-168. 10.1046/j.1365-2249.2002.01800.x.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.